CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.686
EU - Europa 13.507
AS - Asia 10.758
SA - Sud America 1.201
AF - Africa 173
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 12
Totale 42.349
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.506
SG - Singapore 5.156
RU - Federazione Russa 4.271
GB - Regno Unito 3.743
CN - Cina 3.088
FR - Francia 1.122
BR - Brasile 984
IT - Italia 970
DE - Germania 884
IE - Irlanda 786
VN - Vietnam 719
SE - Svezia 705
HK - Hong Kong 690
FI - Finlandia 568
KR - Corea 404
UA - Ucraina 177
IN - India 135
BD - Bangladesh 130
TR - Turchia 99
CA - Canada 95
AR - Argentina 76
JP - Giappone 56
PL - Polonia 49
NG - Nigeria 43
NL - Olanda 42
MX - Messico 41
IQ - Iraq 39
ES - Italia 38
ID - Indonesia 33
ZA - Sudafrica 33
AT - Austria 29
EC - Ecuador 29
VE - Venezuela 26
PK - Pakistan 25
BE - Belgio 24
CO - Colombia 21
PE - Perù 21
TN - Tunisia 21
CL - Cile 18
UZ - Uzbekistan 17
AE - Emirati Arabi Uniti 16
SA - Arabia Saudita 16
AZ - Azerbaigian 15
KE - Kenya 14
MA - Marocco 14
DZ - Algeria 13
LT - Lituania 13
PY - Paraguay 12
UY - Uruguay 11
IL - Israele 10
JO - Giordania 10
PH - Filippine 10
AL - Albania 9
AU - Australia 9
EG - Egitto 9
EU - Europa 9
MY - Malesia 9
PS - Palestinian Territory 9
SN - Senegal 9
JM - Giamaica 8
KG - Kirghizistan 8
NP - Nepal 8
RO - Romania 8
BG - Bulgaria 7
GE - Georgia 7
HU - Ungheria 7
OM - Oman 7
PT - Portogallo 7
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
GA - Gabon 6
TH - Thailandia 6
BH - Bahrain 5
CH - Svizzera 5
GR - Grecia 5
HN - Honduras 5
LB - Libano 5
LV - Lettonia 5
MD - Moldavia 5
PA - Panama 5
RS - Serbia 5
CR - Costa Rica 4
GT - Guatemala 4
IR - Iran 4
KZ - Kazakistan 4
NI - Nicaragua 4
NO - Norvegia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
ET - Etiopia 3
HR - Croazia 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
AO - Angola 2
BB - Barbados 2
BN - Brunei Darussalam 2
CY - Cipro 2
EE - Estonia 2
KH - Cambogia 2
Totale 42.323
Salva come PNG Salva come JPEG
Città #
Southend 2.941
Singapore 2.938
Jacksonville 2.515
Woodbridge 1.526
San Jose 1.440
Ashburn 1.425
Chandler 1.414
Moscow 1.250
Ann Arbor 934
Dallas 934
Houston 835
Dublin 785
Hong Kong 673
The Dalles 521
Verona 448
Wilmington 418
Lawrence 372
Princeton 371
Lancaster 356
Nanjing 304
Beijing 275
Jinan 274
Ho Chi Minh City 263
Sindelfingen 262
New York 245
Los Angeles 233
Shenyang 221
Buffalo 187
Hanoi 171
Kent 149
Hebei 145
Council Bluffs 144
Tianjin 127
Changsha 121
Helsinki 120
Zhengzhou 105
Boardman 97
Milan 95
Haikou 91
Nanchang 90
São Paulo 81
Guangzhou 76
Taizhou 75
Redondo Beach 74
Jiaxing 73
Columbus 71
Orem 71
Hangzhou 70
Ningbo 69
Santa Clara 66
Taiyuan 61
Chennai 50
Norwalk 50
Tokyo 50
Seattle 48
Washington 48
Munich 43
Falls Church 42
Lanzhou 41
Chicago 40
Abuja 39
Da Nang 35
Frankfurt am Main 35
Nuremberg 35
San Francisco 34
Brooklyn 32
Warsaw 32
Philadelphia 30
Rio de Janeiro 30
Amsterdam 28
Stockholm 28
Manchester 27
Rome 27
Haiphong 26
Montreal 26
Toronto 26
Seoul 24
Belo Horizonte 22
Fuzhou 22
London 22
Atlanta 21
Brussels 21
Boston 20
Biên Hòa 19
Turku 19
Auburn Hills 18
Johannesburg 18
Phoenix 18
Falkenstein 17
Tashkent 17
Shanghai 16
Baku 15
Dhaka 15
Lima 15
Brasília 14
Porto Alegre 14
Baghdad 13
Dearborn 13
Denver 13
Fairfield 13
Totale 27.923
Salva come PNG Salva come JPEG
Nome #
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 320
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 310
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 224
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 214
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 211
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 207
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 204
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 204
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 197
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 196
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 194
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 194
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 192
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 186
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 186
[Infection due to hepatitis B virus and host immune response] 185
La regressione della cirrosi epatica: non più un mito. 184
A long term study of hepatitis G virus coinfection in chronic hepatitis B 180
Hepatitis C and cirrhosis 180
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 180
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 179
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 178
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 176
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 176
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 175
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 175
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 173
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 173
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 172
A randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg negative chronic hepatitis B. 170
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 170
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 170
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 165
[Relationships between clinico-therapeutic parameters and immunological status in patients with lung cancer] 163
Autonomic dysfunction and hemodynamic derangement in cirrhotic cardiomyopathy 163
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 163
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 161
Malattie autoimmuni del fegato 160
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 160
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 159
A controlled trial of alpha-2 recombinant interferon for chronic HBeAg positive hepatitis 159
Carriage of the EGF RS4444903 A>G functional polimorphism associates with disease progression in chronic HBV infection. 159
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 158
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 157
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 157
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 157
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 157
A controlled trial of thymopentin therapy in HBV-DNA positive chronic hepatitis B 156
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 155
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily clinical parameters. 155
A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B 154
Progression to cirrhosis, hepatocellular carcinoma and liver related mortality in chronic hepatitis B patients in Italy. 154
[Presence of HBsAg and IgG on the membrane of hepatic cells in patients with acute and chronic hepatitis] 152
Natural course and prognostic factors of hepatitis B. 152
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 152
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 151
Natural history of hepatitis B and prognostic factors of disease progression 150
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 150
Natural history of hepatitis B virus infection and disease 149
A seven-gene signature (Cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C 149
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 148
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 146
Natural history of chronic hepatitis B 146
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 146
Gestione delle infezioni da virus epatite B secondo le linee guida nazionali ed internazionali. 146
Incidenza e fattori di rischio di epatocarcinoma. 145
Suppressor cell function in chronic active hepatitis 145
Hepatitis C genotypes in patients with dual hepatitis B and C virus infection 144
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 143
How to predictic the outcome of chronic hepatitis B 142
[The side effects associated with the interferon-alpha therapy of chronic viral hepatitis] 139
Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis 139
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 139
Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays 138
Clinical and virological profiles in patients with multiple hepatitis virus infections. 138
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 138
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 137
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 137
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 137
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 137
Efficacy of consensus interferon (CIFN) plus ribavirin (RBV) as initial treatment for chronic hepatitis C patients: an italian multicentre study 137
Effectiveness of interferon alfa in caucasian patients with viral compensated cirrhosis 136
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 136
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 136
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 136
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 135
Reduced serum hepcidin levels in patients with chronic hepatitis C 135
T and K cell function in acute and chronic hepatitis 134
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 133
Attualità in tema di terapia dell’epatite cronica B. 133
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 133
Antibodies to the RNase H domain of hepatitis B virus P protein are associated with ongoing viral replication 132
Suppressor cell activity in viral and non-viral chronic active hepatitis 132
Heteroimmune and autoimmune reactions to liver cell surface antigens in the pathogenesis of acute and chronic hepatitis 131
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 131
Natural history of hepatitis B 131
IL28B genotype, differential expression of intrahepatis interferon-stimulated genes and response to PEG-IFN and ribavirin therapy in an Italian prospective cohort of genotype 1 hepatitis C patients in “real life”. 131
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B 130
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay 130
Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. 130
Totale 16.104
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.436
article - articoli 59.122
book - libri 0
conference - conferenze 63.744
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 12.570
Totale 270.872
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202175 0 0 0 0 0 0 0 0 0 0 0 75
2021/20222.414 148 544 11 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/20256.028 396 508 45 911 387 83 194 264 1.044 403 422 1.371
2025/202614.269 1.307 709 942 2.155 3.383 1.135 1.623 780 1.066 699 233 237
Totale 42.429